Valeant Pharmaceuticals International VRX
-
Noteworthy 5% Fund Ownership Filings Last Week: 2 New And 3 Increased Positions
By Ganaxi Small Cap Movers : Many leading funds, including SAC Capital, Elliott Associates, and Healthcor Group, filed forms 13-D and 13-G (and form 4) with the SEC last week (May 14th to 18th, 2012), indicating that they had amended their ownership in U.S. traded public companies. Based on our ...
-
Noteworthy Insider Buys Last Week In 2 Beaten Down Biotechs, With 4 Other Buys And Sells
By Ganaxi Small Cap Movers : trades. Complete Story »
-
Reasons for selling a stock can be many, but there's only one reason for insiders to buy : they expect the stock to go higher. Looking for a leg-up on where to put some money to work? Here's what a ...
… s what a couple insiders have been doing this week: On Monday, Valeant Pharmaceuticals' ( VRX ) Director, Laurence E. Paul, bought 5k shares of VRX , while on the same day Rosetta Resources ( ROSE ) Executive VP, CFO & Treasurer John E. Hagale …
-
2 Strong Pharmaceuticals To Consider Now, 1 To Avoid
By Income Hunter : Mega large cap Johnson & Johnson ( JNJ ) has long been among my favorite big cap stocks. I thought it appropriate, in this era where so many competitors have fallen off patent cliffs, to see how Johnson & Johnson is holding up. In its first quarter of 2012, Johnson & Johnson ...
-
5 Biotech Stocks To Buy Now For Gains In 2013
By Cris Frangold : Investors hate to be limited, which is why a selection of choices is always better than just one. It helps to compare companies in the same price range or the same industry because not all good buys are right for everyone. Investing is an individualized science. There are some ...
-
New Morningstar Analyst Report for Valeant Pharmaceuticals International Inc.
Valeant's record and disciplined approach give us confidence in its acquisition strategy.
-
5 Biotech Stocks With Massive Upside Potential In 2013
By Cris Frangold : I have had my eye on Vertex Pharmaceuticals ( VRTX ) for awhile now. The stock recently leaped 42% on news of a successful study targeting cystic fibrosis. The combination of Kalydeco and VX-809 was found to have improved the lung function of 46% of patients over a 56 day ...
-
Valeant shares fall as market cools on forecast
(Reuters) - Shares of Valeant Pharmaceuticals International Inc tumbled 9 percent on Thursday after at least one analyst cast doubts about an earnings forecast that initially triggered a sharp rise...
-
Valeant: A Risky Bet For Brave Investors
By Vatalyst : The history of Valeant Pharmaceuticals ( VRX ) is one of constant change. The company's oldest root seems to be ICN Pharmaceuticals, founded in the 1950s by Milan Panic …
-
UPDATE 1-Valeant raises forecast on acquisition boost
May 3 (Reuters) - Valeant Pharmaceuticals International Inc posted a bigger-than-expected adjusted quarterly profit and raised its forecast for the year as acquisitions boost sales, sending its shares to a nine-year high.